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Received December 20, 2011; accepted March 9, 2012AbstractBackground: Treatments for the purposes of curing or more effectively managing metastatic colorectal cancer (CRC) are evolving. Our study
focused on patients with primary CRC with synchronous distant metastasis, and we analyzed the factors influencing patient survival.
Methods: Data review was conducted retrospectively. Clinicopathological parameters included age, sex, site of primary cancer, tumor cell
differentiation, number of liver metastasis, presence of extrahepatic metastasis, treatment of liver metastasis, pre-treatment carcinoembryonic
antigen (CEA) level, status of treatment response, salvage treatment and survival.
Results: A total of 420 patients were identified and considered for our study. Of those, 275 patients (65.4%) had liver-only metastasis, 100
patients (23.8%) had concomitant lung metastasis, and 40 patients (9.5%) had other metastases. Additionally, 145 patients (34.5%) had liver-
directed treatment including surgical resection (28.5%), radiofrequency ablation (RFA) (10.6%) and transcatheter arterial chemoembolization
(TAE) (1.2%). There were 80 patients (19%) with CEA levels < 10, 135 patients (32.1%) with CEA 10e100, and 165 patients (39.2%) with
CEA > 100. There were 200 patients (47.6%) who had received chemotherapy, 130 patients (30.9%) with target therapy, and 40 patients (9.5%)
who had not undergone any salvage treatment. Three significant factors were identified, including treatment of liver metastasis ( p¼ 0.027), pre-
treatment CEA ( p¼ 0.04), and salvage treatment ( p¼ 0.005).
Conclusion: We demonstrated three factors influencing patient survival including treatment of liver metastasis, pre-treatment CEA level, and
salvage treatment. Aggressive treatment of liver metastasis including surgical resection or RFA combined with chemotherapeutic agents appear
to provide an increased rate of survival to patients.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Approximately 20% of patients with colorectal cancer
(CRC) have synchronous liver metastasis at the time of
diagnosis.1 Although major advances in systemic chemo-
therapy have expanded the therapeutic options for these
patients and improved median survival periods from less than
1 year to 20 months or longer, fewer than 10% of those treated* Corresponding author. Dr. Jui-Ho Wang, Division of Colorectal Surgery,
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http://dx.doi.org/10.1016/j.jcma.2012.03.008with chemotherapy alone are still alive at 5 years.2 Long-term
survival of patients with metastatic CRC has only been ach-
ieved in those patients who could undergo primary surgical
resection of metastases.3 Unfortunately, such surgical treat-
ments can only be offered to approximately 10% of the
patients who present with metastases from CRC.4
Treatment choices for CRC with synchronous distant metas-
tasis are evolving, especially those involving cases of liver
metastasis. Given that three classes of chemotherapeutic agents
and two classes of target therapy are currently available in
Taiwan, treatment decision-making and management is more
complicated as the optimum sequencing and dosing of the agents
still remains to be determined. Clinicians are increasingly usinghinese Medical Association. All rights reserved.
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of CRC with synchronous liver metastasis, which have demon-
strated significant improvement in outcomes.5,6
It is important to identify prognostic factors that may help
to determine the most effective CRC treatment response,
thereby increasing patient survival periods. Such an approach
could refine the decision-making and management of CRC
with palliative chemotherapy according to the likelihood of
clinical benefit.7 In this study, we focused on patients with
primary CRC with synchronous liver metastasis and analyzed
the factors influencing survival.
2. Methods
This was a retrospective study conducted at Kaohsiung
Veterans General Hospital, where we reviewed surgical and
pathological records that included all patients treated for CRC
with synchronous distant metastasis from 2002 to 2009.
Patient data were collected into our electronic medical records
database, which included all patient follow-up, including the
latest follow-up or date of demise.
The clinicopathological parameters which we evaluated
included age, sex, site of primary cancer, tumor cell differenti-
ation, number of liver metastasis, presence of extrahepatic
metastasis, treatmentmodality of livermetastasis, pre-treatment
carcinoembryonic antigen (CEA) level (ng/mL), status of
treatment response (according to Response Evaluation Criteria
in Solid Tumors (RECIST) criteria, 1.1 version, 2009), salvage
treatment (chemotherapy or target therapy) and survival period
(months). The patient follow-up period ranged from 1 month to
60 months, and the survival period was calculated from the date
that CRC with synchronous liver metastasis was detected until
the latest follow-up date. Some parameters were excluded from
further analysis due to limited case number, including patients
without resection of the primary tumor (n¼ 20), and patients
treated with radiation only (n¼ 5).
Chemotherapy regimens included conventional FOLFIRI
(irinotecan 180 mg/m2 plus 5-FU and leucovorin) and FOL-
FOX4 (oxaliplatin 85 mg/m2 plus 5-FU and leucovorin). The
target therapy regimen included cetuximab (initial dose
400 mg/m2, weekly dose of 250 mg/m2) plus FOLFIRI and
bevacizumab (5 mg/kg IVover 90 minutes every 2 weeks) plus
FOLFIRI or FOLFOX.
Survival curves were generated according to the Kaplan-
Meier method, and the differences in patient survival periods
were determined by employing the log-rank test. All data were
analyzed by the Statistical Package for the Social Sciences,
version 12.0 (SPSS Inc., Chicago, IL, USA). To determine the
prognostic factors for survival, all variables were tested from
their relationship in the Cox-regression model and the Cox
proportional hazards model. A p value < 0.05 was accepted as
statistically significant.
3. Results
Among the 450 patients who underwent treatment for
CRC with synchronous distant metastasis which wereretrospectively analyzed, 20 patients had perioperative
mortality, 10 patients had concomitant malignancies other than
CRC, and 10 patients died of other disease and thus were
excluded from this study. The clinicopathologic data of the
420 patients identified are summarized in Table 1. Since
complete data on all factors were not available for each
patient, the sample size in this study ranged from 396 to 420 in
the further analysis.
Among these patients, 250 (59.2%) were males. The mean
age was 60.7 13.9 years (range, 29e88), and the median
follow-up time was 20 10.3 months (range, 1e60). Median
overall survival in all patients was 18.5 20 months (range,
1e60). Regarding treatment of the primary tumor, 395 patients
(94%) had resection of the primary tumor, 20 patients (4.7%)
without resection of the primary tumor, and five patients
(1.2%) only underwent radiotherapy. Regarding the actual
number of liver metastases, 215 patients (51.2%) had
uncountable liver metastases, with the balance countable
metastases (27.4% with one lesion, 7.1% with two lesions,
5.9% with three lesions, 3.5% with four lesions, 2.4% with
five lesions, and 2.4% with six lesions). Furthermore, 275
patients (65.4%) had liver-only metastasis, 100 patients had
concomitant lung metastasis, and 40 patients had other
concomitant metastases including bone, ovary, brain, and
carcinomatosis. Regarding the treatment of liver metastasis,
275 patients (65.4%) were without liver-directed treatment, 95
patients (22.6%) had liver resection metastasis, 20 patients
(4.7%) underwent radiofrequency ablation (RFA) or percuta-
neous ethanol injection (PEI), 25 patients (5.9%) had resection
and RFA, and five patients (1.2%) had transcatheter arterial
chemoembolization (TAE).
CEA level was measured within 1 month of detection of the
disease, with the results divided into three groups: < 10,
10e100, and > 100, and 80 patients (19%) with CEA < 10,
135 patients (32.1%) with CEA 10e100, 165 patients (39.2%)
with CEA > 100. Regarding the salvage treatment, 200
patients (47.6%) had chemotherapy, 130 patients (30.9%) were
treated with target therapy, and 40 patients (9.5%) did not have
any salvage treatment. As for the status of treatment response,
315 patients (75%) had a progressive disease, 55 patients
(13.1%) had a partial response, and 15 patients (3.5%) had
a complete response.
Two-year and 3-year survival rates in patients with
treatment of liver metastasis were 75% and 50%, respec-
tively (Fig. 1B). There was no survival difference between
patients with liver-only metastasis or extrahepatic metas-
tasis ( p¼ 0.177, Fig. 1B). In patients with treatment of
liver metastasis, the 2-year survival rate was 75%, and the
3-year survival rate was 50%. Without any treatment of
liver metastasis, survival rates decreased to 20% and 5%,
respectively (Fig. 1C). There were significant differences in
survival between patients with treatment of liver metastasis
( p< 0.001, Fig. 1C, Hazard Ratio (HR): 5.15 in no treat-
ment of liver metastasis), the number of liver metastasis
( p< 0.001, Fig. 1D, HR: 4.4 in uncountable liver metas-
tasis), pre-treatment CEA level ( p¼ 0.004, Fig. 1E, HR: 2.4
in CEA: 10e100, HR: 8.0 in CEA > 100), and different
Table 1
Clinicopathologic data of patients with colorectal cancer with synchronous
liver.
Demographic variables No. of patients (n¼ 420)
Age (y) 60.7 13.9 (29e88)
Sex
Male 250 (59.2%)
Female 170 (40.8%)
Primary tumor site
Right colon 90 (21.4%)
Left colon 215 (51.2%)
Rectum 110 (26.1%)
Tumor cell differentiation
Well differentiation 9 (2.1%)
Moderate differentiation 381 (90.7%)
Poorly differentiation 30 (7.2%)
Primary tumor treatment
Resection 395 (94%)
No resection 20 (4.7%)
Radiotherapy 5 (1.2%)
Number of liver metastasis
Uncountable (S7) 215 (51.2%)
1 115 (27.4%)
2 30 (7.1%)
3 25 (5.9%)
4 15 (3.5%)
5 10 (2.4%)
6 10 (2.4%)
Liver-only metastasis
Yes 275 (65.4%)
No 140 (34.6%)
Concomitant other metastasis
Lung 100 (23.8%)
Bone, ovary, brain, carcinomatosis 40 (9.5%)
Treatment of liver metastasis
Nil 275 (65.4%)
Liver resection 95 (22.6%)
RFA or PEI 20 (4.7%)
Liver resectionþ RFA 25 (5.9%)
TAE 5 (1.2%)
Pre-treatment CEA (ng/ml)
< 10 80 (19%)
10-100 135 (32.1%)
> 100 165 (39.2%)
Salvage treatment
Chemotherapy 200 (47.6%)
Target therapy 130 (30.9%)
Nil 40 (9.5)
Status of treatment response
Progressive disease 315 (75%)
Stable disease 55 (13.1%)
complete response 15 (3.5%)
Median survival (months) 18.5 20 (1e60)
CEA¼ carcinoembryonic antigen; PEI¼ percutaneous ethanol injection;
RFA¼ radiofrequency ablation;TAE¼ transcatheter arterial chemoembolization.
372 C.-W. Hsu et al. / Journal of the Chinese Medical Association 75 (2012) 370e375salvage treatment ( p¼ 0.035, Fig. 1F, HR: 0.39 in chemo-
therapy, HR: 0.29 in target therapy). Factors influencing
survival in the Cox-regression model are shown in Table 2.
There are three factors with significant differences,
including treatment of liver metastasis ( p¼ 0.027), pre-
treatment CEA level ( p¼ 0.04), and salvage treatment
( p¼ 0.005).4. Discussion
Various studies on survival factors for metastatic CRC have
resulted in disparate results. These incongruent results prob-
ably depict differences in patient population and study design,
thus making them difficult to evaluate. In 1983, Lahr et al8
reported several factors predicting survival such as elevated
alkaline phosphatase (ALP), elevated serum bilirubin level, the
location of hepatic metastases (unilateral or bilateral), the
number of metastatic nodes involved, depressed serum
albumin, chemotherapy (given or withheld), and whether or
not the primary colorectal tumor was resected. Schindl et al9
reported in their 2005 study some prognostic factors in CRC
with liver metastases including Dukes Stage, number of
metastases, and serum concentrations of CEA, alkaline phos-
phatase, and albumin. In 2009, Luo et al10 reported that poor
differentiation of the tumor and high CEA level indicate an
unfavorable prognosis. In 2010, Zacharakis et al11 reported
three factors that suggested improved survival in stage IV
CRC: combination chemotherapy, improved performance
status and dermatological complications. This study noted
eight factors which indicated unfavorable survival: worsened
performance status, C-reactive protein > 5 mg/dL, anemia,
anorexia, weight loss > or ¼ 10%, fatigue, hypoalbuminemia,
and blood transfusions. Our study included consecutive non-
selected CRC with synchronous distant metastasis cases
from a single medical center. Based on these settings, we
identify three factors that influence survival: treatment of liver
metastasis, pre-treatment CEA level, and salvage treatment.
High preoperative serum CEA levels are associated with
advanced tumor stage, elevated incidence of recurrence and
reduced survival periods.12 Carcinoembryonic antigen exists
in the embryonic and fetal gut, liver, pancreas, and some adult
organs.13 It is elevated in approximately 40% of CRC14 and
was first mentioned as a factor in 1965.15 In recent studies
involving CRC with liver metastases, CEA is still an inde-
pendent factor influencing survival.10,16
Resection of colorectal liver metastases in selected patients
has evolved as the standard of care during the last 20 years.
Five-year survival rates after resection range from 24% to
58%, averaging 40%, and surgical mortality rates are generally
less than 5%. 17e21 Subgroups with advanced age, comorbid
disease, and synchronous hepatic and colon resection may
have higher procedure-related mortality and worse long-term
outcomes.22 Radiofrequency ablation has been widely
applied to patients with metastatic liver tumors. The vast
majority of published data on efficacy of RFA for CRC liver
metastases come from retrospective series with limited follow-
up (20 months or less); there are no published randomized
trials.23e26 A systematic review of the literature on RFA for
CRC liver metastases reported a wide range of 5-year survival
(14e55%), and local tumor recurrence rates (3.6e60% ).27
Given the evidence that resection improves overall survival,
particularly in the absence of extrahepatic disease, a system-
atic review of the literature by an expert panel from American
Society of Clinical Oncology (ASCO) concluded that there is
not enough evidence to support the use of RFA over
Fig. 1. (A) Overall survival curves; (B) survival curves according to liver-only metastasis and extrahepatic metastasis ( p¼ 0.177); (C) survival curves according to
treatment of liver metastasis ( p< 0.001). 2-year and 3-year survival in patients with treatment of liver metastasis were 75% and 50% respectively; and 20% and
5%, respectively, if no treatment of liver metastasis was given (HR: 5.15); (D) survival curves according to number of liver metastasis ( p< 0.001, HR: 4.4); (E)
survival curves according to pre-treatment CEA level ( p¼ 0.004, HR: 2.4 in CEA: 10e100, HR: 8.0 in CEA: > 100); (F) survival curves according to salvage
treatment ( p¼ 0.035, HR:0.29 in target therapy, HR: 0.39 in chemotherapy). HR¼ hazard ratio.
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metastases.27
Chemotherapy is a well-established salvage treatment
strategy in CRC with synchronous liver metastasis and hasbeen shown to independently predict survival.28 Combination
chemotherapy regimens including irinotecan and oxaliplatin in
combination with 5-FU, with or without a biological agent,
have improved response rates to as high as 50% and overall
Table 2
Factors influencing survival by multivariate Cox regression model.
Standard error p-value 95% CI Hazard ratio 95% CI
Age 0.018 0.364 0.951-1.019
Liver-only metastasis 0.462 0.579 0.313-1.915
Number of liver metastasis 0.555 0.469 0.226-1.986
Countable Reference e
Uncountable 4.4 1.818-10.707
Treatment of liver metastasis 0.725 0.027 0.048-0.829
Yes Reference e
No 5.15 1.862-10.886
Pre-treatment CEA level 0.330 0.040 1.032-3.758
<10 Reference e
10-100 2.4 0.535-11.2
>100 8.0 1.744-37.228
Salvage treatment 0.400 0.005 0.148-0.714
Nil Reference e
Chemotherapy 0.39 0.135-1.187
Target therapy 0.29 0.098-0.959
CI¼ confidence interval.
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the importance of combination chemotherapy as an indepen-
dent predictor of survival for CRC with synchronous liver
metastasis.
Resection of the primary tumor in CRC with unresectable
metastases is still a matter of debate. In 2007, Costi et al31
reported palliative resection of primary CRC should be
pursued in patientswith unresectable distantmetastasis (without
carcinomatosis), and, intraoperatively, whenever the primary
tumor is technically resectable. In 2010, Scabini et al32 also
reported that an inability to perform cancer resection is associ-
atedwith poor prognosis in symptomatic stage IVCRC, and also
has reduced survival in the short term. However, all of these
results come from retrospective data, so selection bias and other
clinical factors that are not accounted for may explain this
observation. Prospective, randomized surgical trials are needed
to test the role of primary tumor resection in this setting.33 In our
study, most of the patients (94%) received resection of the
primary tumor, including curative resection and palliative
resection when the primary tumor is resectable.
There are some limitations to our study. First, this is
a retrospective analysis of our experience. Second, there must
be a selection bias in salvage treatment. It has to be assumed
that, in general, enhanced patient survival was obtained when
patients began treatment in better general physical condition,
and then received more aggressive chemotherapeutic agents.
However, this is very difficult to assess on a retrospective
basis. These findings deserve further randomized-control trials
and validation in large-scale studies.
In conclusion, management of CRC with synchronous
distant metastasis is a medical challenge. In this retrospective
study, we clearly demonstrated three factors that influence
patient survival periods including treatment of liver metastasis,
pre-treatment CEA level, and salvage treatment with chemo-
therapeutic agents. Aggressive treatment of liver metastasis,
including surgical resection or RFA combined with chemo-
therapeutic agents, seems to present patients with a recog-
nizeable survival benefit.References
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